5-(1-(6-Aminopyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(1-(6-Aminopyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one
• 英文别名: 5-[1-(6-aminopyridin-3-yl)-5-(trifluoromethyl)pyrazol-3-yl]-3-methyl-1,3,4-oxadiazol-2-one
• 化学式: C₁₂H₉F₃N₆O₂
• 分子量: 326.23
• InChiKey: ONIUXLPXHIZOAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  98.6
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-Methyl-5-(1-(6-nitropyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2(3H)-one 以 乙腈 为溶剂， 生成 5-(1-(6-Aminopyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS

  摘要：

  本发明涉及描述如下式（I）的化合物及其药学上可接受的盐，其调节钙释放活化的钙（CRAC）通道的活性。本发明还描述了式（I）的化合物及其药物组合物，用于治疗、管理和/或减轻与调节钙释放活化的钙（CRAC）通道相关的疾病、疾病、综合征或病状。

  公开号：

  US20150111925A1

文献信息

• Substituted pyrazole compounds as CRAC modulators
  申请人：LUPIN LIMITED

  公开号：US09409898B2

  公开（公告）日：2016-08-09

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

  本发明涉及描述如下式(I)的化合物及其药学上可接受的盐，其调节钙释放激活的钙(CRAC)通道的活性。该发明还描述了式(I)的化合物及含有这种化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活的钙(CRAC)通道相关的疾病、疾病、综合症或病症的严重程度。
• US9409898B2
  申请人：——

  公开号：US9409898B2

  公开（公告）日：2016-08-09
• [EN] SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLE EN TANT QUE MODULATEURS DE CRAC
  申请人：LUPIN LTD

  公开号：WO2013164773A1

  公开（公告）日：2013-11-07

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release- activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.
• SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20150111925A1

  公开（公告）日：2015-04-23

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

  本发明涉及描述如下式（I）的化合物及其药学上可接受的盐，其调节钙释放活化的钙（CRAC）通道的活性。本发明还描述了式（I）的化合物及其药物组合物，用于治疗、管理和/或减轻与调节钙释放活化的钙（CRAC）通道相关的疾病、疾病、综合征或病状。